Filaggrin mutations in relation to skin barrier and atopic dermatitis in early infancy.


Journal

The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041

Informations de publication

Date de publication:
03 2022
Historique:
accepted: 24 10 2021
pubmed: 27 10 2021
medline: 22 4 2022
entrez: 26 10 2021
Statut: ppublish

Résumé

Loss-of-function mutations in the skin barrier gene filaggrin (FLG) increase the risk of atopic dermatitis (AD), but their role in skin barrier function, dry skin and eczema in infancy is unclear. To determine the role of FLG mutations in impaired skin barrier function, dry skin, eczema and AD at 3 months of age and throughout infancy. FLG mutations were analysed in 1836 infants in the Scandinavian population-based PreventADALL study. Transepidermal water loss (TEWL), dry skin, eczema and AD were assessed at 3, 6 and 12 months of age. FLG mutations were observed in 166 (9%) infants. At 3 months, carrying FLG mutations was not associated with impaired skin barrier function (TEWL > 11·3 g m FLG mutations were not associated with impaired skin barrier function or dry skin in general at 3 months of age, but increased the risk for eczema, and for dry skin on the trunk and extensor limb surfaces at 3 and 6 months.

Sections du résumé

BACKGROUND
Loss-of-function mutations in the skin barrier gene filaggrin (FLG) increase the risk of atopic dermatitis (AD), but their role in skin barrier function, dry skin and eczema in infancy is unclear.
OBJECTIVES
To determine the role of FLG mutations in impaired skin barrier function, dry skin, eczema and AD at 3 months of age and throughout infancy.
METHODS
FLG mutations were analysed in 1836 infants in the Scandinavian population-based PreventADALL study. Transepidermal water loss (TEWL), dry skin, eczema and AD were assessed at 3, 6 and 12 months of age.
RESULTS
FLG mutations were observed in 166 (9%) infants. At 3 months, carrying FLG mutations was not associated with impaired skin barrier function (TEWL > 11·3 g m
CONCLUSIONS
FLG mutations were not associated with impaired skin barrier function or dry skin in general at 3 months of age, but increased the risk for eczema, and for dry skin on the trunk and extensor limb surfaces at 3 and 6 months.

Identifiants

pubmed: 34698386
doi: 10.1111/bjd.20831
doi:

Substances chimiques

FLG protein, human 0
Filaggrin Proteins 0
Intermediate Filament Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

544-552

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

© 2021 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Références

Silverberg JI. Public health burden and epidemiology of atopic dermatitis. Dermatol Clin 2017; 35:283-9.
Asher MI, Montefort S, Björkstén B et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006; 368:733-43.
Kay J, Gawkrodger DJ, Mortimer MJ, Jaron AG. The prevalence of childhood atopic eczema in a general population. J Am Acad Dermatol 1994; 30:35-9.
Čepelak I, Dodig S, Pavić I. Filaggrin and atopic march. Biochem Med (Zagreb) 2019; 29:020501.
Benson H. Anatomy and Physiology Laboratory Textbook, Intermediate Version, Fetal Pig. Dubuque, IA: Wm. C. Brown Publishers; 1996.
Smith FJ, Irvine AD, Terron-Kwiatkowski A et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet 2006; 38:337-42.
Palmer CN, Irvine AD, Terron-Kwiatkowski A et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38:441-6.
Irvine AD, McLean WH. Breaking the (un)sound barrier: filaggrin is a major gene for atopic dermatitis. J Invest Dermatol 2006; 126:1200-2.
Barker JN, Palmer CN, Zhao Y et al. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. J Invest Dermatol 2007; 127:564-7.
Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med 2011; 365:1315-27.
Bonnelykke K, Pipper CB, Tavendale R et al. Filaggrin gene variants and atopic diseases in early childhood assessed longitudinally from birth. Pediatr Allergy Immunol 2010; 21:954-61.
Bisgaard H, Simpson A, Palmer CN et al. Gene-environment interaction in the onset of eczema in infancy: filaggrin loss-of-function mutations enhanced by neonatal cat exposure. PLOS MED 2008; 5:e131.
Marenholz I, Nickel R, Ruschendorf F et al. Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march. J Allergy Clin Immunol 2006; 118:866-71.
Smieszek SP, Welsh S, Xiao C et al. Correlation of age-of-onset of atopic dermatitis with Filaggrin loss-of-function variant status. Sci Rep 2020; 10:2721.
Bohme M, Svensson A, Kull I, Wahlgren CF. Hanifin’s and Rajka’s minor criteria for atopic dermatitis: which do 2-year-olds exhibit? J Am Acad Dermatol 2000; 43:785-92.
Rehbinder EM, Winger AJ, Landro L et al. Dry skin and skin barrier in early infancy. Br J Dermatol 2019; 181:218-9.
Werner Y, Lindberg M. Transepidermal water loss in dry and clinically normal skin in patients with atopic dermatitis. Acta Derm Venereol 1985; 65:102-5.
Berents TL, Lødrup Carlsen KC, Mowinckel P et al. Transepidermal water loss in infancy associated with atopic eczema at 2 years of age: a population-based cohort study. Br J Dermatol 2017; 177:e35-7.
Lodrup Carlsen KC, Rehbinder EM, Skjerven HO et al. Preventing Atopic Dermatitis and ALLergies in Children - the PreventADALL study. Allergy 2018; 73:2063-70.
Skjerven HO, Rehbinder EM, Vettukattil R et al. Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial. Lancet 2020; 395:951-61.
Rogiers V. EEMCO guidance for the assessment of transepidermal water loss in cosmetic sciences. Skin Pharmacol Appl Skin Physiol 2001; 14:117-28.
Berents TL, Carlsen KC, Mowinckel P et al. Skin barrier function and Staphylococcus aureus colonization in vestibulum nasi and fauces in healthy infants and infants with eczema: a population-based cohort study. PLOS ONE 2015; 10:e0130145.
Rehbinder EM, Advocaat Endre KM, Lodrup Carlsen KC et al. Predicting skin barrier dysfunction and atopic dermatitis in early infancy. J Allergy Clin Immunol Pract 2020; 8:664-73.e5.
Carson CG, Rasmussen MA, Thyssen JP et al. Clinical presentation of atopic dermatitis by filaggrin gene mutation status during the first 7 years of life in a prospective cohort study. PLOS ONE 2012; 7:e48678.
Williams HC, Burney PG, Hay RJ et al. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol 1994; 131:383-96.
Williams HC, Burney PG, Strachan D, Hay RJ. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. II. Observer variation of clinical diagnosis and signs of atopic dermatitis. Br J Dermatol 1994; 131:397-405.
Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol 1994; 131:406-16.
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980; 92:44-7.
Thyssen JP, Bikle DD, Elias PM. Evidence that loss-of-function filaggrin gene mutations evolved in northern Europeans to favor intracutaneous vitamin D3 Production. Evol Biol 2014; 41:388-96.
Park KY, Park MK, Seok J et al. Clinical characteristics of Korean patients with filaggrin-related atopic dermatitis. Clin Exp Dermatol 2016; 41:595-600.
Bager P, Wohlfahrt J, Thyssen JP, Melbye M. Filaggrin genotype and skin diseases independent of atopic dermatitis in childhood. Pediatr Allergy Immunol 2016; 27:162-8.
Flohr C, England K, Radulovic S et al. Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. Br J Dermatol 2010; 163:1333-6.
Baurecht H, Irvine AD, Novak N et al. Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data. J Allergy Clin Immunol 2007; 120:1406-12.
Levin J, Friedlander SF, Del Rosso JQ. Atopic dermatitis and the stratum corneum: part 1: the role of filaggrin in the stratum corneum barrier and atopic skin. J Clin Aesthet Dermatol 2013; 6:16-22.
Kezic S, Kemperman PM, Koster ES et al. Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum. J Invest Dermatol 2008; 128:2117-19.
Pendaries V, Malaisse J, Pellerin L et al. Knockdown of filaggrin in a three-dimensional reconstructed human epidermis impairs keratinocyte differentiation. J Invest Dermatol 2014; 134:2938-46.
Yuki T, Tobiishi M, Kusaka-Kikushima A et al. Impaired tight junctions in atopic dermatitis skin and in a skin-equivalent model treated with interleukin-17. PLOS ONE 2016; 11:e0161759.
Marenholz I, Volz A, Ziegler A et al. Genetic analysis of the epidermal differentiation complex (EDC) on human chromosome 1q21: chromosomal orientation, new markers, and a 6-Mb YAC contig. Genomics 1996; 37:295-302.
Böhme M, Söderhäll C, Kull I et al. Filaggrin mutations increase the risk for persistent dry skin and eczema independent of sensitization. J Allergy Clin Immunol 2012; 129:1153-5.
McAleer MA, Jakasa I, Raj N et al. Early-life regional and temporal variation in filaggrin-derived natural moisturizing factor, filaggrin-processing enzyme activity, corneocyte phenotypes and plasmin activity: implications for atopic dermatitis. Br J Dermatol 2018; 179:431-41.
Thyssen JP, Ross-Hansen K, Johansen JD et al. Filaggrin loss-of-function mutation R501X and 2282del4 carrier status is associated with fissured skin on the hands: results from a cross-sectional population study. Br J Dermatol 2012; 166:46-53.
Ziyab AH, Ewart S, Lockett GA et al. Expression of the filaggrin gene in umbilical cord blood predicts eczema risk in infancy: a birth cohort study. Clin Exp Allergy 2017; 47:1185-92.
Endre KMA, Landrø L, LeBlanc M et al. Diagnosing atopic dermatitis in infancy using established diagnostic criteria: a cohort study. Br J Dermatol 2021; https://doi.org/10.1111/bjd.19831.

Auteurs

A Hoyer (A)

Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

E M Rehbinder (EM)

Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Dermatology and Venerology, Oslo University Hospital, Oslo, Norway.

M Färdig (M)

Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.

S Asad (S)

Dermatology Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.

K C Lødrup Carlsen (KC)

Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.

K M A Endre (KMA)

Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Dermatology and Venerology, Oslo University Hospital, Oslo, Norway.

B Granum (B)

Department of Environmental Health, Norwegian Institute of Public Health, Oslo, Norway.

G Haugen (G)

Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Division of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway.

G Hedlin (G)

Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.

C Monceyron Jonassen (C)

Faculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.
Genetic Unit, Centre for Laboratory Medicine, Østfold Hospital Trust, Kalnes, Norway.

S Katayama (S)

Folkhälsan Research Center, Helsinki, Finland.
Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.
Stem Cells and Metabolism Research Program, University of Helsinki, Helsinki, Finland.

J R Konradsen (JR)

Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.

L Landrø (L)

Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Department of Dermatology and Venerology, Oslo University Hospital, Oslo, Norway.

M LeBlanc (M)

Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway.

C A Olsson Mägi (CA)

Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.

K Rudi (K)

Faculty of Chemistry, Biotechnology and Food Science, Norwegian University of Life Sciences, Ås, Norway.

H O Skjerven (HO)

Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.

A C Staff (AC)

Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Division of Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway.

R Vettukattil (R)

Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway.

M Bradley (M)

Dermatology Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.

B Nordlund (B)

Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.

C Söderhäll (C)

Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH